Answers are grounded in this paper and cite their sources.
In this study, a series of novel thiochroman-4-one derivatives functionalized with a pyrimidine moiety were synthesized and fully characterized via1H NMR, 13C NMR, and HRMS. Bioactivity assays demonstrated that compound 5c exhibited the most potent in vitro α-glucosidase inhibition with an IC50 of 15.61 μg/mL, which was superior to that of the positive control acarbose (237.48 μg/mL). Compound 5e showed the strongest in vitro antibacterial activity against Xanthomonas axonopodis pv. citri (Xac) with an EC50 of 10.29 μg/mL, which outperformed both commercial bactericides bismerthiazol (145.65 μg/mL) and thiodiazole copper (227.65 μg/mL). Meanwhile, the molecular docking analysis revealed that compound 5c interacts strongly with the active site of human intestinal α-glucosidase (PDB ID: 3TOP) via several binding interactions, exhibiting a binding energy of −8.8 kcal/mol. Furthermore, in-silico ADMET and drug-likeness predictions indicated that compounds 5c and 5e possessed favorable pharmacokinetic profiles and low toxic risks, satisfying the basic requirements for prospective therapeutic leads. This work establishes a convenient synthetic strategy for pyrimidine-substituted thiochroman-4-one analogues, and provides promising lead candidates for developing dual-functional α-glucosidase inhibitors and antibacterial agents.
No takes yet. Share an insight, caveat, or question.
Zhuang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: